Literature DB >> 1355018

Pharmacokinetic optimisation of antiemetic therapy.

M Campbell1, D N Bateman.   

Abstract

Antiemetic drugs are used to treat nausea and vomiting due to a variety of causes and have a wide range of pharmacological properties. The choice of drug will, therefore, depend in part on the condition being treated. The drugs can be classified as dopamine antagonists (including phenothiazines and nonphenothiazines), corticosteroids, cannabinoids, benzodiazepines, serotonin antagonists, antihistamines and anticholinergics. There is very little evidence of a relationship between plasma drug concentrations and either their efficacy or the incidence of adverse effects with most antiemetic drugs. With drugs for which concentration-effect studies have been performed, e.g. the benzodiazepines and antihistamines, the effects monitored have not been directly relevant to their use as antiemetics. Antiemetics are used widely, for example, in cancer chemotherapy. Nonetheless, apart from metoclopramide, little work has been done on the influence of indicators of systemic disease on the pharmacokinetics of antiemetic drugs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1355018     DOI: 10.2165/00003088-199223020-00006

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  73 in total

Review 1.  Pharmacological agents affecting emesis. A review (Part I).

Authors:  F Mitchelson
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

2.  The metabolism of ondansetron.

Authors:  D A Saynor; C M Dixon
Journal:  Eur J Cancer Clin Oncol       Date:  1989

Review 3.  The pharmacokinetics of corticosteroid agents.

Authors:  E J Begg; H C Atkinson; N Gianarakis
Journal:  Med J Aust       Date:  1987-01-05       Impact factor: 7.738

4.  Preliminary studies of the pharmacokinetics and pharmacodynamics of prochlorperazine in healthy volunteers.

Authors:  W B Taylor; D N Bateman
Journal:  Br J Clin Pharmacol       Date:  1987-02       Impact factor: 4.335

Review 5.  Nabilone. A preliminary review of its pharmacological properties and therapeutic use.

Authors:  A Ward; B Holmes
Journal:  Drugs       Date:  1985-08       Impact factor: 9.546

Review 6.  Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines).

Authors:  D M Paton; D R Webster
Journal:  Clin Pharmacokinet       Date:  1985 Nov-Dec       Impact factor: 6.447

7.  Lorazepam pharmacodynamics and pharmacokinetics in children.

Authors:  M V Relling; R K Mulhern; R K Dodge; D Johnson; J A Pieper; G K Rivera; W E Evans
Journal:  J Pediatr       Date:  1989-04       Impact factor: 4.406

8.  Diphenhydramine kinetics following intravenous, oral, and sublingual dimenhydrinate administration.

Authors:  J M Scavone; B G Luna; J S Harmatz; L von Moltke; D J Greenblatt
Journal:  Biopharm Drug Dispos       Date:  1990-04       Impact factor: 1.627

9.  Disposition of lorazepam in human beings: enterohepatic recirculation and first-pass effect.

Authors:  R J Herman; J D Van Pham; C B Szakacs
Journal:  Clin Pharmacol Ther       Date:  1989-07       Impact factor: 6.875

10.  Methylprednisolone pharmacokinetics after intravenous and oral administration.

Authors:  S M Al-Habet; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1989-03       Impact factor: 4.335

View more
  2 in total

1.  Clinical management of dying patients.

Authors:  J Gavrin; C R Chapman
Journal:  West J Med       Date:  1995-09

2.  Development and validation of a sensitive LC-MS method for the determination of promethazine hydrochloride in human plasma and urine.

Authors:  Ping Liu; Sun Liang; Ben-Jie Wang; Rui-Chen Guo
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2009 Jul-Sep       Impact factor: 2.569

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.